Effective Bladder Preservation Strategy with Low-dose Radiation Therapy and Concurrent Intraarterial Chemotherapy for Muscle-invasive Bladder Cancer

Overview

Journal Radiat Med

Specialties Nuclear Medicine
Oncology
Radiology

Date 2008 Aug 8

PMID 18683571

Citations 5

Authors

Hitoshi Ikushima

Seiji Iwamoto

Kyohsuke Osaki

Shunsuke Furutani

Kyoh Yamashita

Takashi Kawanaka

Akiko Kubo

Yoshihiro Takegawa

Takaharu Kudoh

Hiroomi Kanayama

Hiromu Nishitani

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT).

Methods And Materials: . Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment.

Results: Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity.

Conclusion: Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects.

Citing Articles

KIF22 promotes bladder cancer progression by activating the expression of CDCA3.

Li K, Li S, Tang S, Zhang M, Ma Z, Wang Q Int J Mol Med. 2021; 48(6).

PMID: 34633053 PMC: 8522959. DOI: 10.3892/ijmm.2021.5044.

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.

Schuettfort V, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K World J Urol. 2020; 39(6):1757-1768.

PMID: 32995918 PMC: 8217031. DOI: 10.1007/s00345-020-03436-0.

[Follow-up of bladder cancer : The right examinations at the right time].

Olbert P, Goebell P, Hegele A Urologe A. 2018; 57(6):693-701.

PMID: 29663062 DOI: 10.1007/s00120-018-0641-3.

External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer.

Matsumoto Y, Samma S, Fukui S, Nakai Y, Kagebayashi Y, Torimoto K Indian J Urol. 2015; 31(1):52-6.

PMID: 25624577 PMC: 4300573. DOI: 10.4103/0970-1591.139563.

Conservative treatment of invasive bladder cancer.

Rene N, Cury F, Souhami L Curr Oncol. 2009; 16(4):36-47.

PMID: 19672423 PMC: 2722049. DOI: 10.3747/co.v16i4.411.

References

Eapen L, Stewart D, Collins J, Peterson R . Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol. 2004; 172(4 Pt 1):1276-80. DOI: 10.1097/01.ju.0000140456.42509.b6. View

Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R . Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996; 14(1):119-26. DOI: 10.1200/JCO.1996.14.1.119. View

Shipley W, Kaufman D, Zehr E, Heney N, Lane S, Thakral H . Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002; 60(1):62-7; discussion 67-8. DOI: 10.1016/s0090-4295(02)01650-3. View

Kaufman D, Winter K, Shipley W, Heney N, Chetner M, Souhami L . The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on.... Oncologist. 2000; 5(6):471-6. DOI: 10.1634/theoncologist.5-6-471. View

Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott K, Martus P . Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998; 40(1):121-7. DOI: 10.1016/s0360-3016(97)00579-8. View

Sell A, Jakobsen A, NERSTROM B, Sorensen B, Steven K, BARLEBO H . Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical.... Scand J Urol Nephrol Suppl. 1991; 138:193-201. View

. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration. Br J Urol. 1995; 75(2):206-13. DOI: 10.1111/j.1464-410x.1995.tb07313.x. View

Pollack A, Zagars G, Swanson D . Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994; 30(2):267-77. DOI: 10.1016/0360-3016(94)90004-3. View

Rodel C, Grabenbauer G, Kuhn R, Zorcher T, Papadopoulos T, Dunst J . Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys. 2002; 52(5):1303-9. DOI: 10.1016/s0360-3016(01)02771-7. View

10.

Shearer R, Chilvers C, BLOOM H, Bliss J, Horwich A, Babiker A . Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol. 1988; 62(6):558-64. DOI: 10.1111/j.1464-410x.1988.tb04426.x. View

11.

SKINNER D, Daniels J, Russell C, Lieskovsky G, Boyd S, Nichols P . The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145(3):459-64; discussion 464-7. DOI: 10.1016/s0022-5347(17)38368-4. View

12.

. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354(9178):533-40. View

13.

Mameghan H, Fisher R, Mameghan J, Brook S . Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1995; 31(2):247-54. DOI: 10.1016/0360-3016(94)E0135-7. View

14.

Sumiyoshi Y, Hashine K, Karashima T, Kasahara K, Inoue Y . Preliminary results of bladder preservation by concurrent intraarterial chemotherapy and radiotherapy for muscle-invasive bladder cancer. Int J Urol. 1998; 5(3):225-9. DOI: 10.1111/j.1442-2042.1998.tb00594.x. View

15.

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

16.

Michaelson M, Shipley W, Heney N, Zietman A, Kaufman D . Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer. 2004; 90(3):578-81. PMC: 2409604. DOI: 10.1038/sj.bjc.6601580. View

17.

Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K . Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47(1):13-47. DOI: 10.1016/s0360-3016(99)00559-3. View

18.

Miyanaga N, Akaza H, Okumura T, SEKIDO N, Kawai K, Shimazui T . A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol. 2000; 7(2):41-8. DOI: 10.1046/j.1442-2042.2000.00137.x. View

19.

Hagan M, Winter K, Kaufman D, Wajsman Z, Zietman A, Heney N . RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003; 57(3):665-72. DOI: 10.1016/s0360-3016(03)00718-1. View

20.

Gospodarowicz M, Hawkins N, Rawlings G, Connolly J, Jewett M, Thomas G . Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989; 142(6):1448-53; discussion 1453-4. DOI: 10.1016/s0022-5347(17)39122-x. View